{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:59:31Z","timestamp":1793825971704,"version":"4.6.1"},"reference-count":226,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","ajkd.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1053\/j.ajkd.2024.08.003","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T18:39:22Z","timestamp":1731955162000},"page":"135-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD"],"prefix":"10.1053","volume":"85","author":[{"given":"Sankar D.","family":"Navaneethan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri L.","family":"Cavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Estrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cybele","family":"Ghossein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Alp","family":"Ikizler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Koncicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"St. Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"William","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib2","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1053\/j.ajkd.2022.12.001","article-title":"US Renal Data System 2022 annual data report: epidemiology of kidney disease in the United States","volume":"81","author":"Johansen","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"23","key":"10.1053\/j.ajkd.2024.08.003_bib3","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1053\/j.ajkd.2024.08.003_bib4","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.003_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1053\/j.ajkd.2024.08.003_bib6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1053\/j.ajkd.2024.08.003_bib7","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1053\/j.ajkd.2024.08.003_bib8","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.003_bib9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1053\/j.ajkd.2024.08.003_bib10","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.003_bib11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","article-title":"A\u00a0unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease","volume":"79","author":"Delgado","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.003_bib12","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.kint.2023.05.013","article-title":"Trends and perspectives for improving quality of chronic kidney disease care: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"104","author":"Eckardt","year":"2023","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","article-title":"The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"99","author":"Shlipak","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.003_bib14","first-page":"318","article-title":"Principles and Practice of Screening for Disease (World Health Organization, 1968)","volume":"16","author":"Wilson","year":"1968","journal-title":"Br J Gen Pract"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.003_bib15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2471\/BLT.07.050112","article-title":"Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years","volume":"86","author":"Andermann","year":"2008","journal-title":"Bull World Health Organ"},{"issue":"13","key":"10.1053\/j.ajkd.2024.08.003_bib16","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA"},{"issue":"7","key":"10.1053\/j.ajkd.2024.08.003_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.26230","article-title":"Estimated prevalence and testing for albuminuria in US adults at risk for chronic kidney disease","volume":"6","author":"Chu","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"20","key":"10.1053\/j.ajkd.2024.08.003_bib18","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"12","key":"10.1053\/j.ajkd.2024.08.003_bib19","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.2215\/CJN.07860621","article-title":"Food insecurity and kidney disease: symptoms of structural racism","volume":"16","author":"Mokiao","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2024.08.003_bib20","article-title":"Social determinants of health and chronic kidney disease","volume":"12","author":"Qui\u00f1ones","year":"2020","journal-title":"Cureus"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2215\/CJN.08350719","article-title":"Particulate matter and albuminuria, glomerular filtration rate, and incident CKD","volume":"15","author":"Blum","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.003_bib22","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrneph.2018.11","article-title":"Environmental pollution and kidney diseases","volume":"14","author":"Xu","year":"2018","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.003_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101419","article-title":"Efficacy and safety profile of SGLT2 inhibitors in the elderly: how is the benefit\/risk balance?","volume":"49","author":"Scheen","year":"2023","journal-title":"Diabetes Metab"},{"issue":"4 suppl","key":"10.1053\/j.ajkd.2024.08.003_bib24","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ajkd.2024.08.003_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100710","article-title":"Discordance between creatinine-based and cystatin C-based estimated GFR: interpretation according to performance compared to measured GFR","volume":"5","author":"Wang","year":"2023","journal-title":"Kidney Med"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.003_bib26","first-page":"493","article-title":"Estimation of kidney function in patients with primary neuromuscular diseases: is serum cystatin C\u00a0a\u00a0better marker of kidney function than creatinine?","volume":"35","author":"Aldenbratt","year":"2022","journal-title":"J\u00a0Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.003_bib27","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1111\/bcp.15639","article-title":"Estimated glomerular filtration rate based on creatinine, cystatin C, \u03b2-trace protein and \u03b22 microglobulin in patients undergoing nontraumatic lower extremity amputation","volume":"89","author":"Iversen","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib28","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.kint.2021.12.010","article-title":"A\u00a0prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors","volume":"101","author":"Costa e Silva","year":"2022","journal-title":"Kidney Int"},{"issue":"10 suppl","key":"10.1053\/j.ajkd.2024.08.003_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1681\/ASN.20203110S111d","article-title":"Assessment of estimated glomerular filtration rate in a cohort of 1200 cancer patients using serum creatinine and cystatin C [abstract TH-OR40]","volume":"31","author":"Costa e Silva","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.003_bib30","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10157-015-1115-1","article-title":"Renal function evaluation in patients with cancer who were scheduled to receive carboplatin or S-1","volume":"19","author":"Shibata","year":"2015","journal-title":"Clin Exp Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2024.08.003_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28733","article-title":"Assessment of kidney function using inulin-based and estimated glomerular filtration rates before and after allogeneic hematopoietic stem cell transplantation in pediatric patients","volume":"67","author":"Matsuoka","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.003_bib32","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1002\/ehf2.13404","article-title":"Serum creatinine and cystatin C-based estimates of glomerular filtration rate are misleading in acute heart failure","volume":"8","author":"Swolinsky","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.003_bib33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/j.ajkd.2016.09.016","article-title":"Cystatin C versus creatinine for GFR estimation in CKD due to heart failure","volume":"69","author":"Kervella","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12882-023-03136-y","article-title":"Impact of race-independent equations on estimating glomerular filtration rate for the assessment of kidney dysfunction in liver disease","volume":"24","author":"St\u00e4mmler","year":"2023","journal-title":"BMC Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.003_bib35","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1053\/j.ajkd.2015.09.022","article-title":"Creatinine versus cystatin C for estimating GFR in patients with liver cirrhosis","volume":"67","author":"Torre","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2024.08.003_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100727","article-title":"Cystatin C as a GFR estimation marker in acute and chronic illness: a systematic review","author":"Adingwupu","year":"2023","journal-title":"Kidney Med"},{"issue":"10","key":"10.1053\/j.ajkd.2024.08.003_bib37","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.5858\/arpa.2021-0306-CP","article-title":"Improved performance in measurement of serum cystatin C by laboratories participating in the College of American Pathologists 2019 CYS Survey","volume":"146","author":"Karger","year":"2022","journal-title":"Arch Pathol Lab Med"},{"issue":"19","key":"10.1053\/j.ajkd.2024.08.003_bib38","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.003_bib39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa2203769","article-title":"Cystatin C-based equation to estimate GFR without the inclusion of race and sex","volume":"388","author":"Pottel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.003_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.7326\/M20-4366","article-title":"Development and validation of a modified full age spectrum creatinine-based equation to estimate glomerular filtration rate: a cross-sectional analysis of pooled data","volume":"174","author":"Pottel","year":"2021","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1053\/j.ajkd.2024.08.003_bib41","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1681\/ASN.0000000000000227","article-title":"CKD-EPI and EKFC GFR estimating equations: performance and other considerations for selecting equations for implementation in adults","volume":"34","author":"Inker","year":"2023","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.003_bib43","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1053\/j.ajkd.2022.08.004","article-title":"An endorsement of the removal of race from GFR estimation equations: a position statement from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative","volume":"80","author":"Kramer","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib44","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.ajkd.2021.03.008","article-title":"Reassessing the inclusion of race in diagnosing kidney diseases: an interim report from the NKF-ASN Task Force","volume":"78","author":"Delgado","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.003_bib45","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.kint.2020.10.047","article-title":"Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease","volume":"99","author":"Pierce","year":"2021","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.003_bib46","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.ajkd.2023.06.008","article-title":"Performance of GFR estimating equations in young adults","volume":"83","author":"Inker","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib47","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/lgbt.2021.0219","article-title":"Method of calculating renal function estimates could inappropriately exclude transgender patients receiving gender-affirming hormone therapy from pre-exposure prophylaxis eligibility","volume":"9","author":"Patel","year":"2022","journal-title":"LGBT Health"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.003_bib48","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1053\/j.ajkd.2024.01.522","article-title":"A\u00a0holistic framework for the evaluation of kidney function in a gender-diverse landscape","volume":"84","author":"Turino Miranda","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1373\/clinchem.2008.106567","article-title":"Current issues in measurement and reporting of urinary albumin excretion","volume":"55","author":"Miller","year":"2009","journal-title":"Clin Chem"},{"key":"10.1053\/j.ajkd.2024.08.003_bib50","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejrad.2019.01.007","article-title":"Point of care creatinine testing in diagnostic imaging: a feasibility study within the outpatient computed tomography setting","volume":"112","author":"Snaith","year":"2019","journal-title":"Eur J Radiol"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.003_bib51","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/1715163520902495","article-title":"Community pharmacist identification of chronic kidney disease using point-of-care technology: a pilot study","volume":"153","author":"Donovan","year":"2020","journal-title":"Can Pharm J (Ott)"},{"key":"10.1053\/j.ajkd.2024.08.003_bib52","doi-asserted-by":"crossref","DOI":"10.1177\/2054358120922617","article-title":"Community pharmacy-based eGFR screening for early detection of CKD in high risk patients","volume":"7","author":"Papastergiou","year":"2020","journal-title":"Can J Kidney Health Dis"},{"issue":"9","key":"10.1053\/j.ajkd.2024.08.003_bib53","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.2337\/dc20-2715","article-title":"Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations","volume":"44","author":"Stempniewicz","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ajkd.2024.08.003_bib57","author":"Miller"},{"issue":"20","key":"10.1053\/j.ajkd.2024.08.003_bib58","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1001\/jama.2022.15404","article-title":"Reported awareness and adoption of 2021 estimated glomerular filtration rate equations among US clinical laboratories, March 2022","volume":"328","author":"Genzen","year":"2022","journal-title":"JAMA"},{"issue":"8","key":"10.1053\/j.ajkd.2024.08.003_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221325","article-title":"Primary care physicians\u2019 perceptions of barriers and facilitators to management of chronic kidney disease: a mixed methods study","volume":"14","author":"Sperati","year":"2019","journal-title":"PLoS One"},{"issue":"7","key":"10.1053\/j.ajkd.2024.08.003_bib60","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1007\/s11606-019-04975-y","article-title":"Primary care physicians\u2019 perceived barriers to nephrology referral and co-management of patients with CKD: a qualitative study","volume":"34","author":"Greer","year":"2019","journal-title":"J\u00a0Gen Intern Med"},{"issue":"8","key":"10.1053\/j.ajkd.2024.08.003_bib61","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.2215\/CJN.00730111","article-title":"Chronic kidney disease awareness among individuals with clinical markers of kidney dysfunction","volume":"6","author":"Tuot","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2024.08.003_bib62","author":"Larson"},{"issue":"9","key":"10.1053\/j.ajkd.2024.08.003_bib63","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1001\/jamapediatrics.2020.1124","article-title":"Comparison of number and geographic distribution of pediatric subspecialists and patient proximity to specialized care in the US between 2003 and 2019","volume":"174","author":"Turner","year":"2020","journal-title":"JAMA Pediatr"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib67","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.mayocpiqo.2023.12.004","article-title":"Show Me CKDintercept Initiative: a collective impact approach to improve population health in Missouri","volume":"8","author":"Laue","year":"2024","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib68","first-page":"36","article-title":"Collective impact","volume":"9","author":"Kania","year":"2011","journal-title":"Stanf Soc Innov Rev"},{"issue":"7","key":"10.1053\/j.ajkd.2024.08.003_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100493","article-title":"Impact of kidney failure risk prediction clinical decision support on monitoring and referral in primary care management of CKD: a randomized pragmatic clinical trial","volume":"4","author":"Samal","year":"2022","journal-title":"Kidney Med"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.003_bib70","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3122\/jabfm.2016.05.160020","article-title":"Use of clinical decision support to improve primary care identification and management of chronic kidney disease (CKD)","volume":"29","author":"Litvin","year":"2016","journal-title":"J\u00a0Am Board Fam Med"},{"issue":"9153","key":"10.1053\/j.ajkd.2024.08.003_bib71","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)07368-1","article-title":"Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study","volume":"353","author":"Gaede","year":"1999","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.003_bib72","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.3377","article-title":"Effect of 2 clinical decision support strategies on chronic kidney disease outcomes in primary care: a cluster randomized trial","volume":"1","author":"Carroll","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1053\/j.ajkd.2024.08.003_bib73","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jamainternmed.2024.0708","article-title":"Electronic health record population health management for chronic kidney disease care: a cluster randomized clinical trial","volume":"184","author":"Jhamb","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"13","key":"10.1053\/j.ajkd.2024.08.003_bib74","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2311708","article-title":"Pragmatic trial of hospitalization rate in chronic kidney disease","volume":"390","author":"Vazquez","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.003_bib75","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.kint.2022.03.019","article-title":"Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"101","year":"2022","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2024.08.003_bib76","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1681\/ASN.0000000000000401","article-title":"The role of genetic testing in adult CKD","volume":"35","author":"Knoers","year":"2024","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2024.08.003_bib77","first-page":"S219","article-title":"Chronic kidney disease and risk management: standards of care in diabetes\u20132024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib78","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate \u2018dip\u2019 upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"Kraus","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.003_bib79","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.kint.2020.10.042","article-title":"Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice","volume":"99","author":"Oshima","year":"2021","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.003_bib80","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib81","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib82","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1161\/HYPERTENSIONAHA.119.13131","article-title":"Association between acute fall in estimated glomerular filtration rate after treatment for primary aldosteronism and long-term decline in renal function","volume":"74","author":"Kobayashi","year":"2019","journal-title":"Hypertension"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib83","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfad249","article-title":"Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial","volume":"17","author":"M\u00e5rup","year":"2024","journal-title":"Clin Kidney J"},{"issue":"8","key":"10.1053\/j.ajkd.2024.08.003_bib84","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.003_bib85","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/HYPERTENSIONAHA.121.17323","article-title":"Albuminuria testing in hypertension and diabetes: an individual-participant data meta-analysis in a global consortium","volume":"78","author":"Shin","year":"2021","journal-title":"Hypertension"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib86","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ekir.2022.01.1066","article-title":"Integrating CKD into US primary care: bridging the knowledge and implementation gaps","volume":"7","author":"Vassalotti","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib87","doi-asserted-by":"crossref","DOI":"10.1136\/bmjoq-2021-001591","article-title":"Improving annual albuminuria testing for individuals with diabetes","volume":"11","author":"Kam","year":"2022","journal-title":"BMJ Open Qual"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib88","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12882-019-1324-z","article-title":"Improving proteinuria screening with mailed smartphone urinalysis testing in previously unscreened patients with hypertension: a randomized controlled trial","volume":"20","author":"Leddy","year":"2019","journal-title":"BMC Nephrol"},{"issue":"10407","key":"10.1053\/j.ajkd.2024.08.003_bib89","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S0140-6736(23)00876-0","article-title":"Participation rate and yield of two home-based screening methods to detect increased albuminuria in the general population in the Netherlands (THOMAS): a prospective, randomised, open-label implementation study","volume":"402","author":"Van Mil","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.003_bib90","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2015.18202","article-title":"Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis","volume":"315","author":"Tangri","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.003_bib91","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1053\/j.ajkd.2021.05.018","article-title":"A\u00a0predictive model for progression of CKD to kidney failure based on routine laboratory tests","volume":"79","author":"Zacharias","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1053\/j.ajkd.2024.08.003_bib92","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1007\/s00125-021-05444-0","article-title":"Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease","volume":"64","author":"Chan","year":"2021","journal-title":"Diabetologia"},{"issue":"8","key":"10.1053\/j.ajkd.2024.08.003_bib93","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.ekir.2022.05.004","article-title":"Development and external validation of a machine learning model for progression of CKD","volume":"7","author":"Ferguson","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"9","key":"10.1053\/j.ajkd.2024.08.003_bib94","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.2337\/dc22-0698","article-title":"Development and validation of prediction models of adverse kidney outcomes in the population with and without diabetes","volume":"45","author":"Grams","year":"2022","journal-title":"Diabetes Care"},{"issue":"21","key":"10.1053\/j.ajkd.2024.08.003_bib95","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1001\/jama.2019.17379","article-title":"Development of risk prediction equations for incident chronic kidney disease","volume":"322","author":"Nelson","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib96","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000519920","article-title":"Clinical utility of KidneyIntelX in early stages of diabetic kidney disease in the CANVAS Trial","volume":"53","author":"Lam","year":"2022","journal-title":"Am J Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.003_bib97","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.kint.2023.06.020","article-title":"Development of an adaptive clinical web-based prediction tool for kidney replacement therapy in children with chronic kidney disease","volume":"104","author":"Ng","year":"2023","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib98","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib99","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2024.08.003_bib100","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.003_bib101","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1681\/ASN.2010040355","article-title":"Predicting the risk for dialysis or death in IgA nephropathy","volume":"22","author":"Berthoux","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4 suppl 2","key":"10.1053\/j.ajkd.2024.08.003_bib102","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2019.12.001","article-title":"KDOQI clinical practice guideline for vascular access: 2019 update","volume":"75","author":"Lok","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"18","key":"10.1053\/j.ajkd.2024.08.003_bib103","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1016\/j.jacc.2016.02.055","article-title":"Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a large contemporary, multiethnic population","volume":"67","author":"Rana","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.003_bib104","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association\u2019s PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.003_bib105","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.kint.2018.01.009","article-title":"Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate","volume":"93","author":"Grams","year":"2018","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2024.08.003_bib106","doi-asserted-by":"crossref","DOI":"10.1177\/20543581231215865","article-title":"Implementing a formalized risk-based approach to determine candidacy for multidisciplinary CKD care: a descriptive cohort study","volume":"10","author":"Donald","year":"2023","journal-title":"Can J Kidney Health Dis"},{"key":"10.1053\/j.ajkd.2024.08.003_bib107","doi-asserted-by":"crossref","DOI":"10.1177\/2054358117722782","article-title":"Risk-based triage for nephrology referrals using the Kidney Failure Risk Equation","volume":"4","author":"Hingwala","year":"2017","journal-title":"Can J Kidney Health Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib108","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12882-019-1269-2","article-title":"Patient and provider experience and perspectives of a risk-based approach to multidisciplinary chronic kidney disease care: a mixed methods study","volume":"20","author":"Smekal","year":"2019","journal-title":"BMC Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2024.08.003_bib109","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1016\/j.ekir.2023.09.001","article-title":"Implementation of the Kidney Failure Risk Equation in a United States nephrology clinic","volume":"8","author":"Patel","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"7","key":"10.1053\/j.ajkd.2024.08.003_bib110","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.2215\/CJN.10880821","article-title":"Keys to driving implementation of the new kidney care models","volume":"17","author":"Kshirsagar","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5 suppl","key":"10.1053\/j.ajkd.2024.08.003_bib111","first-page":"S1","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"issue":"3 suppl","key":"10.1053\/j.ajkd.2024.08.003_bib112","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.003_bib113","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.ajkd.2021.09.010","article-title":"KDOQI US commentary on the KDIGO 2020 clinical practice guideline for diabetes management in CKD","volume":"79","author":"Mottl","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"3 suppl 1","key":"10.1053\/j.ajkd.2024.08.003_bib114","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI clinical practice guideline for nutrition in CKD: 2020 update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib115","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ecl.2016.04.016","article-title":"The psychosocial burden of obesity","volume":"45","author":"Sarwer","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"6 suppl","key":"10.1053\/j.ajkd.2024.08.003_bib116","first-page":"S103","article-title":"Advancing exercise science for better health outcomes across the spectrum of chronic kidney disease","volume":"33","author":"Bohm","year":"2023","journal-title":"J\u00a0Ren Nutr"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib117","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.ajkd.2021.09.013","article-title":"KDOQI US commentary on the 2021 KDIGO clinical practice guideline for the management of blood pressure in CKD","volume":"79","author":"Drawz","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"18","key":"10.1053\/j.ajkd.2024.08.003_bib118","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1056\/NEJMra1700312","article-title":"Nutritional management of chronic kidney disease","volume":"377","author":"Kalantar-Zadeh","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2024.08.003_bib119","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jand.2018.05.023","article-title":"Medical nutrition therapy for patients with non-dialysis-dependent chronic kidney disease: barriers and solutions","volume":"118","author":"Kramer","year":"2018","journal-title":"J\u00a0Acad Nutr Diet"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib120","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.ajkd.2023.09.003","article-title":"KDOQI commentary on the KDIGO 2022 update to the clinical practice guideline for diabetes management in CKD","volume":"83","author":"Mottl","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.003_bib121","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"De Boer","year":"2022","journal-title":"Kidney Int"},{"issue":"22","key":"10.1053\/j.ajkd.2024.08.003_bib122","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.003_bib123","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1681\/ASN.2020050682","article-title":"Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: a nationwide study","volume":"32","author":"Fu","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2024.08.003_bib124","first-page":"S179","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes\u20142024","volume":"47","year":"2023","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.003_bib125","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3390\/v3060920","article-title":"Pattern recognition receptors and the innate immune response to viral infection","volume":"3","author":"Thompson","year":"2011","journal-title":"Viruses"},{"issue":"10","key":"10.1053\/j.ajkd.2024.08.003_bib126","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1111\/dom.15194","article-title":"Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020","volume":"25","author":"Nicholas","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib127","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/phar.2083","article-title":"Pharmacist intervention for blood pressure control in patients with diabetes and\/or chronic kidney disease","volume":"38","author":"Anderegg","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib128","first-page":"56","article-title":"Comprehensive medication management and medication adherence for chronic conditions","volume":"22","author":"Brummel","year":"2016","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.003_bib129","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/pop.2017.0167","article-title":"Impact of comprehensive medication management on hospital readmission rates","volume":"21","author":"Budlong","year":"2018","journal-title":"Popul Health Manag"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.003_bib130","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3122\/jabfm.2019.04.180376","article-title":"Primary care providers believe that comprehensive medication management improves their work-life","volume":"32","author":"Funk","year":"2019","journal-title":"J\u00a0Am Board Fam Med"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.003_bib131","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.amjmed.2020.12.008","article-title":"Assessing the impact of comprehensive medication management on achievement of the quadruple aim","volume":"134","author":"McFarland","year":"2021","journal-title":"Am J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib132","first-page":"185","article-title":"Medication therapy management: 10 years of experience in a large integrated health care system","volume":"16","author":"Ramalho de Oliveira","year":"2010","journal-title":"J\u00a0Manag Care Pharm"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib133","doi-asserted-by":"crossref","first-page":"26","DOI":"10.15585\/mmwr.mm6601e1","article-title":"Vital signs: decrease in incidence of diabetes-related end-stage renal disease among American Indians\/Alaska Natives\u2014United States, 1996-2013","volume":"66","author":"Bullock","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib134","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1053\/j.ajkd.2017.09.017","article-title":"Population health for CKD and diabetes: lessons from the Indian Health Service","volume":"71","author":"Narva","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"10365","key":"10.1053\/j.ajkd.2024.08.003_bib135","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib136","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-Kidney trial","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1053\/j.ajkd.2024.08.003_bib137","first-page":"1051","article-title":"Pharmacokinetic properties of dapagliflozin in hemodialysis and peritoneal dialysis patients","volume":"18","author":"Barreto","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2024.08.003_bib138","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2215\/CJN.0000000000000232","article-title":"Extending SGLT2 inhibitor use for people undergoing dialysis?","volume":"18","author":"St Peter","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4 suppl","key":"10.1053\/j.ajkd.2024.08.003_bib140","first-page":"S1","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","year":"2020","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ajkd.2024.08.003_bib141","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1042\/CS20171298","article-title":"SGLT2 inhibition and kidney protection","volume":"132","author":"Nespoux","year":"2018","journal-title":"Clin Sci (Lond)"},{"issue":"19","key":"10.1053\/j.ajkd.2024.08.003_bib142","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"issue":"10424","key":"10.1053\/j.ajkd.2024.08.003_bib143","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"10.1053\/j.ajkd.2024.08.003_bib144","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2337\/dc21-0529","article-title":"Prescribing trends of antidiabetes medications in patients with type 2 diabetes and diabetic kidney disease, a cohort study","volume":"44","author":"Harris","year":"2021","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib145","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/j.ajkd.2022.11.017","article-title":"Predictors, disparities, and facility-level variation: SGLT2 inhibitor prescription among US veterans with CKD","volume":"82","author":"Gregg","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"24","key":"10.1053\/j.ajkd.2024.08.003_bib146","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"issue":"20","key":"10.1053\/j.ajkd.2024.08.003_bib147","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A\u00a0synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.003_bib148","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib149","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ehjcvp\/pvac054","article-title":"Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease","volume":"9","author":"Filippatos","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"10193","key":"10.1053\/j.ajkd.2024.08.003_bib150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1053\/j.ajkd.2024.08.003_bib151","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1007\/s00125-021-05529-w","article-title":"The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials","volume":"64","author":"Lin","year":"2021","journal-title":"Diabetologia"},{"issue":"19","key":"10.1053\/j.ajkd.2024.08.003_bib152","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.003_bib153","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2024.08.003_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100502","article-title":"Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection","volume":"14","author":"Michos","year":"2023","journal-title":"Am J Prev Cardiol"},{"issue":"8","key":"10.1053\/j.ajkd.2024.08.003_bib155","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1053\/j.ajkd.2024.08.003_bib156","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.003_bib157","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.003_bib158","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2024.08.003_bib159","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"24","key":"10.1053\/j.ajkd.2024.08.003_bib160","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2024.08.003_bib161","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.003_bib162","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2337\/dc22-1889","article-title":"Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 Trials","volume":"46","author":"Heerspink","year":"2023","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1053\/j.ajkd.2024.08.003_bib163","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"10.1053\/j.ajkd.2024.08.003_bib164","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1042\/CS20171299","article-title":"Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review","volume":"132","author":"Boyle","year":"2018","journal-title":"Clin Sci (Lond)"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.003_bib165","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.ajkd.2024.08.003_bib166","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsb\u00f8ll","year":"2012","journal-title":"BMJ"},{"issue":"9","key":"10.1053\/j.ajkd.2024.08.003_bib167","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/dom.14443","article-title":"Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis","volume":"23","author":"Mann","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2024.08.003_bib168","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1053\/j.ajkd.2024.08.003_bib169","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2215\/CJN.0000000000000266","article-title":"Racial and ethnic disparities and facility-level variation in GLP-1 RA prescription among US veterans with CKD","volume":"18","author":"Gregg","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib170","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1681\/ASN.0000000000000292","article-title":"VALOR-CKD: a multicenter, randomized, double-blind placebo-controlled trial evaluating veverimer in slowing progression of CKD in patients with metabolic acidosis","volume":"35","author":"Tangri","year":"2024","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2024.08.003_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100736","article-title":"The fruit and veggies for kidney health study: a prospective randomized trial","volume":"5","author":"Kitzman","year":"2023","journal-title":"Kidney Med"},{"issue":"9","key":"10.1053\/j.ajkd.2024.08.003_bib172","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40264-014-0196-1","article-title":"Drug-induced hyperkalemia","volume":"37","author":"Ben Salem","year":"2014","journal-title":"Drug Saf"},{"issue":"10208","key":"10.1053\/j.ajkd.2024.08.003_bib173","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"issue":"41","key":"10.1053\/j.ajkd.2024.08.003_bib174","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"issue":"1 suppl","key":"10.1053\/j.ajkd.2024.08.003_bib176","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5414\/CNP92S106","article-title":"Food as medicine for CKD: implications for disadvantaged populations","volume":"93","author":"Crews","year":"2020","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2024.08.003_bib177","author":"Crews"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib178","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"7","year":"2017","journal-title":"Kidney Int Suppl (2011)"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib179","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100028","article-title":"Comparative effectiveness of allopurinol and febuxostat in gout management","volume":"1","author":"O\u2019Dell","year":"2022","journal-title":"NEJM Evid"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.003_bib180","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1053\/j.ajkd.2024.08.003_bib181","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/1471-2474-14-363","article-title":"Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout","volume":"14","author":"Dalbeth","year":"2013","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib182","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cpt.161","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update","volume":"99","author":"Saito","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.003_bib183","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/bcp.13798","article-title":"Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!","volume":"85","author":"Stamp","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1053\/j.ajkd.2024.08.003_bib184","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1053\/j.ajkd.2024.08.003_bib185","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1053\/j.ajkd.2024.08.003_bib186","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40261-014-0238-6","article-title":"Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease","volume":"34","author":"Wason","year":"2014","journal-title":"Clin Drug Investig"},{"issue":"10","key":"10.1053\/j.ajkd.2024.08.003_bib189","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41584-021-00657-4","article-title":"Management of gout in chronic kidney disease: a G-CAN consensus statement on the research priorities","volume":"17","author":"Stamp","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib190","first-page":"S1","article-title":"KDIGO clinical practice guideline for lipid management in chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"13","key":"10.1053\/j.ajkd.2024.08.003_bib191","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1053\/j.ajkd.2024.08.003_bib192","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1681\/ASN.2016050562","article-title":"Global cardiovascular and renal outcomes of reduced GFR","volume":"28","author":"Thomas","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib193","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M13-2453","article-title":"Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline","volume":"160","author":"Tonelli","year":"2014","journal-title":"Ann Intern Med"},{"issue":"9784","key":"10.1053\/j.ajkd.2024.08.003_bib194","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib195","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1053\/j.ajkd.2024.08.003_bib196","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib197","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/jamacardio.2016.4652","article-title":"Absolute rates of heart failure, coronary heart disease, and stroke in chronic kidney disease: an analysis of 3 community-based cohort studies","volume":"2","author":"Bansal","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"21","key":"10.1053\/j.ajkd.2024.08.003_bib198","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1016\/j.jacc.2019.02.071","article-title":"Burden and outcomes of heart failure hospitalizations in adults with chronic kidney disease","volume":"73","author":"Bansal","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1053\/j.ajkd.2024.08.003_bib199","volume":"11","author":"Lidgard","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib200","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jacc.2007.03.037","article-title":"The Framingham predictive instrument in chronic kidney disease","volume":"50","author":"Weiner","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.003_bib201","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","article-title":"Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease","volume":"93","author":"Toth","year":"2018","journal-title":"Kidney Int"},{"issue":"23","key":"10.1053\/j.ajkd.2024.08.003_bib202","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2019.03.501","article-title":"Aspirin for primary prevention of cardiovascular events","volume":"73","author":"Abdelaziz","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.003_bib203","article-title":"Antiplatelet agents for chronic kidney disease","volume":"2","author":"Natale","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"17","key":"10.1053\/j.ajkd.2024.08.003_bib204","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJMoa1915925","article-title":"Management of coronary disease in patients with advanced kidney disease","volume":"382","author":"Bangalore","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2024.08.003_bib205","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1053\/j.ajkd.2024.08.003_bib206","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1097\/01.ASN.0000135969.33773.0B","article-title":"\u201cRenalism\u201d: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency","volume":"15","author":"Chertow","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"13","key":"10.1053\/j.ajkd.2024.08.003_bib207","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1161\/CIRCULATIONAHA.107.696765","article-title":"Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction","volume":"116","author":"Herzog","year":"2007","journal-title":"Circulation"},{"issue":"7","key":"10.1053\/j.ajkd.2024.08.003_bib208","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1710933","article-title":"Outcomes after angiography with sodium bicarbonate and acetylcysteine","volume":"378","author":"Weisbord","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2024.08.003_bib209","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2215\/CJN.01860217","article-title":"eGFR and albuminuria in relation to risk of incident atrial fibrillation: a meta-analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study","volume":"12","author":"Bansal","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"23","key":"10.1053\/j.ajkd.2024.08.003_bib210","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.003_bib211","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A\u00a0randomized controlled trial comparing apixaban with the vitamin k antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 Study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"issue":"19","key":"10.1053\/j.ajkd.2024.08.003_bib212","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/CIRCULATIONAHA.123.065614","article-title":"Associations of apixaban dose with safety and effectiveness outcomes in patients with atrial fibrillation and severe chronic kidney disease","volume":"148","author":"Xu","year":"2023","journal-title":"Circulation"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.003_bib213","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ekir.2021.10.001","article-title":"Implantable loop recorder monitoring and the incidence of previously unrecognized atrial fibrillation in patients on hemodialysis","volume":"7","author":"Koplan","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"20","key":"10.1053\/j.ajkd.2024.08.003_bib215","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.2019.17725","article-title":"Association of baclofen with encephalopathy in patients with chronic kidney disease","volume":"322","author":"Muanda","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib218","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/j.ackd.2017.10.003","article-title":"Pragmatic use of kidney function estimates for drug dosing: the tide is turning","volume":"25","author":"Hudson","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib219","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1053\/j.ajkd.2021.02.342","article-title":"Principles of kidney pharmacotherapy for the nephrologist: core curriculum 2021","volume":"78","author":"Vondracek","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib220","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1053\/j.ajkd.2020.04.010","article-title":"Performance of indexed and nonindexed estimated GFR","volume":"76","author":"Titan","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.ajkd.2024.08.003_bib221","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.2215\/CJN.03940321","article-title":"Association of polypharmacy with kidney disease progression in adults with CKD","volume":"16","author":"Kimura","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.003_bib222","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1053\/j.ajkd.2017.02.374","article-title":"Targeted deprescribing in an outpatient hemodialysis unit: a quality improvement study to decrease polypharmacy","volume":"70","author":"McIntyre","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.003_bib223","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1053\/j.ajkd.2017.05.025","article-title":"Deprescribing in CKD: the proof is in the process","volume":"70","author":"Whittaker","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1053\/j.ajkd.2024.08.003_bib224","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1111\/jgs.17312","article-title":"Evidence of a gabapentinoid and diuretic prescribing cascade among older adults with lower back pain","volume":"69","author":"Read","year":"2021","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.003_bib225","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/jgs.15800","article-title":"Assessing the scope and appropriateness of prescribing cascades","volume":"67","author":"McCarthy","year":"2019","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib227","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/j.ajkd.2021.09.020","article-title":"Too many for too few: finding appropriate nephrology referrals for patients with CKD that optimize outcomes","volume":"79","author":"Chu","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib228","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1053\/j.ajkd.2021.06.028","article-title":"Nephrology referral based on laboratory values, kidney failure risk, or both: a study using Veterans Affairs Health System data","volume":"79","author":"Duggal","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1053\/j.ajkd.2024.08.003_bib229","first-page":"1234","article-title":"Needs and considerations for standardization of kidney disease education in patients with advanced CKD","volume":"18","author":"Shukla","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2024.08.003_bib230","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1007\/s00467-019-04417-1","article-title":"The brain in pediatric chronic kidney disease-the intersection of cognition, neuroimaging, and clinical biomarkers","volume":"35","author":"Harshman","year":"2020","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2024.08.003_bib231","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1177\/0009922816666882","article-title":"Adolescents\u2019 perceptions of transition importance, readiness, and likelihood of future success: the role of anticipatory guidance","volume":"55","author":"Syverson","year":"2016","journal-title":"Clin Pediatr"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib232","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/j.ackd.2016.11.005","article-title":"Targeting access to kidney care via telehealth: the VA experience","volume":"24","author":"Crowley","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.003_bib233","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/ckj\/sfz096","article-title":"Home Run\u2014results of a chronic kidney disease telemedicine patient education study","volume":"13","author":"Easom","year":"2019","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib234","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12882-022-02740-8","article-title":"A\u00a0randomized controlled trial to evaluate and assess the effect of comprehensive pre-end stage kidney disease education on home dialysis use in veterans, rationale and design","volume":"23","author":"Shukla","year":"2022","journal-title":"BMC Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.003_bib235","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD","volume":"63","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2024.08.003_bib236","article-title":"Planning vascular access creation: the promising role of the kidney failure risk equation","author":"Marques da Silva","year":"2023","journal-title":"J\u00a0Vasc Access"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.003_bib237","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1177\/11297298221084799","article-title":"Is there a role of the kidney failure risk equation in optimizing timing of vascular access creation in pre-dialysis patients?","volume":"24","author":"Kuningas","year":"2023","journal-title":"J\u00a0Vasc Access"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.003_bib238","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1053\/j.ajkd.2023.09.024","article-title":"Development and validation of the rating of CKD Knowledge Among Older Adults (Know-CKD) with kidney failure","volume":"83","author":"Koch-Weser","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib239","doi-asserted-by":"crossref","first-page":"29","DOI":"10.7326\/M22-1543","article-title":"Effectiveness of an intervention to improve decision making for older patients with advanced chronic kidney disease: a randomized controlled trial","volume":"176","author":"Ladin","year":"2023","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.003_bib240","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/j.ajkd.2019.01.030","article-title":"Use of a decision aid for patients considering peritoneal dialysis and in-center hemodialysis: a randomized controlled trial","volume":"74","author":"Subramanian","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.003_bib241","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.kint.2023.10.001","article-title":"Conservative kidney management and kidney supportive care: core components of integrated care for people with kidney failure","volume":"105","author":"Davison","year":"2024","journal-title":"Kidney Int"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638624009776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638624009776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T10:10:12Z","timestamp":1747908612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638624009776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":226,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0272638624009776"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.08.003","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.","name":"copyright","label":"Copyright"}]}}